dual anti-CS-1/anti-BCMA CAR T-cell therapy (Wuhan Sian Medical Technology)

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug Namedual anti-CS-1/anti-BCMA CAR T-cell therapy (Wuhan Sian Medical Technology)
Drug Alias Namedual anti-BCMA/anti-CS-1 CAR T-cell therapy (Wuhan Sian Medical Technology)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionSLAM family member 7 modulatorsTumor necrosis factor ligand superfamily member 13 modulators
TargetsSLAM family member 7Tumor necrosis factor ligand superfamily member 13
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesWuhan Sian Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWuhan Sian Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A